Current application of selective COX-2 inhibitors in cancer prevention and treatment.

M. Suzanne Stratton, David S Alberts

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The multistep process of carcinogenesis, which can take many years, provides many opportunities for intervention to inhibit disease progression. Effective chemoprevention agents may reduce the risk of cancer by inhibiting the initiation stage of carcinoma through induction of apoptosis or DNA repair in cells harboring mutations, or they may act to prevent promotion of tumor growth. Similarly, chemoprevention may entail blocking cancer progression to an invasive phenotype. Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. These COX-2 data have contributed to initiation of clinical trials testing COX-2 inhibitors for the chemoprevention of a wide variety of cancers that overexpress COX-2.

Original languageEnglish (US)
Pages (from-to)37-51
Number of pages15
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number5 Suppl 4
StatePublished - May 2002

Fingerprint

Cyclooxygenase 2 Inhibitors
Celecoxib
Chemoprevention
Cyclooxygenase 2
Neoplasms
Carcinogenesis
Adenomatous Polyposis Coli
Therapeutics
DNA Repair
Disease Progression
Clinical Trials
Apoptosis
Carcinoma
Phenotype
Mutation
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

Current application of selective COX-2 inhibitors in cancer prevention and treatment. / Stratton, M. Suzanne; Alberts, David S.

In: Oncology (Williston Park, N.Y.), Vol. 16, No. 5 Suppl 4, 05.2002, p. 37-51.

Research output: Contribution to journalArticle

@article{0782b4c979ed4917bccbda41b432124f,
title = "Current application of selective COX-2 inhibitors in cancer prevention and treatment.",
abstract = "The multistep process of carcinogenesis, which can take many years, provides many opportunities for intervention to inhibit disease progression. Effective chemoprevention agents may reduce the risk of cancer by inhibiting the initiation stage of carcinoma through induction of apoptosis or DNA repair in cells harboring mutations, or they may act to prevent promotion of tumor growth. Similarly, chemoprevention may entail blocking cancer progression to an invasive phenotype. Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. These COX-2 data have contributed to initiation of clinical trials testing COX-2 inhibitors for the chemoprevention of a wide variety of cancers that overexpress COX-2.",
author = "Stratton, {M. Suzanne} and Alberts, {David S}",
year = "2002",
month = "5",
language = "English (US)",
volume = "16",
pages = "37--51",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "5 Suppl 4",

}

TY - JOUR

T1 - Current application of selective COX-2 inhibitors in cancer prevention and treatment.

AU - Stratton, M. Suzanne

AU - Alberts, David S

PY - 2002/5

Y1 - 2002/5

N2 - The multistep process of carcinogenesis, which can take many years, provides many opportunities for intervention to inhibit disease progression. Effective chemoprevention agents may reduce the risk of cancer by inhibiting the initiation stage of carcinoma through induction of apoptosis or DNA repair in cells harboring mutations, or they may act to prevent promotion of tumor growth. Similarly, chemoprevention may entail blocking cancer progression to an invasive phenotype. Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. These COX-2 data have contributed to initiation of clinical trials testing COX-2 inhibitors for the chemoprevention of a wide variety of cancers that overexpress COX-2.

AB - The multistep process of carcinogenesis, which can take many years, provides many opportunities for intervention to inhibit disease progression. Effective chemoprevention agents may reduce the risk of cancer by inhibiting the initiation stage of carcinoma through induction of apoptosis or DNA repair in cells harboring mutations, or they may act to prevent promotion of tumor growth. Similarly, chemoprevention may entail blocking cancer progression to an invasive phenotype. Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. These COX-2 data have contributed to initiation of clinical trials testing COX-2 inhibitors for the chemoprevention of a wide variety of cancers that overexpress COX-2.

UR - http://www.scopus.com/inward/record.url?scp=0036560261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036560261&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 37

EP - 51

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 5 Suppl 4

ER -